Prebiotic Supplement for Acute GVHD
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine whether the carbohydrate prebiotic (dietary supplement) known as galacto-oligosaccharide (GOS) can modulate the microbiome (the bacteria in the gut) and help prevent graft-versus host disease (GVHD) after allogeneic stem cell transplant. The study has two two parts. In phase 1, the best dose of GOS will be evaluated. In phase 2, using the best dose of GOS, participants will be randomized to receive GOS or a placebo (maltodextrin, a common food additive that is not known to affect the microbiome) so that the effect of GOS can be determined.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot be on active treatment with other prebiotics, probiotics, herbal supplements, or antibiotics (except preventive antibiotics) when you enroll.
What data supports the effectiveness of the treatment Galacto-oligosaccharide for acute GVHD?
Research shows that galacto-oligosaccharides (GOS) can promote the growth of beneficial gut bacteria, which may help protect the intestinal barrier during infections. Additionally, GOS has been shown to have a preventive effect against colorectal cancer in animal studies, suggesting potential benefits for gut health.12345
Is the prebiotic supplement Galacto-oligosaccharide safe for humans?
How is the prebiotic treatment Galacto-oligosaccharide unique for acute GVHD?
Galacto-oligosaccharide (GOS) is unique because it is a prebiotic that specifically promotes the growth of beneficial gut bacteria like bifidobacteria, which can help improve gut health and potentially modulate immune responses. This is different from traditional treatments for acute GVHD, which often focus on suppressing the immune system rather than enhancing gut microbiota.411121314
Research Team
Anthony Sung, MD
Principal Investigator
Duke Health
Mitchell Horwitz, MD
Principal Investigator
Duke Health
Eligibility Criteria
Adults aged 18-80 planning to undergo a stem cell transplant for cancer or other illnesses, with a good performance status. Not eligible if using antibiotics (except prophylactic), prebiotics, probiotics, herbal supplements unless stopped before joining; also excluded if pregnant/lactating, have certain digestive conditions, or are in specific other GVHD trials.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Phase I Treatment
Participants receive GOS at dose levels 0.75g, 1.5g, and 2.9g/day to determine the provisional maximum tolerated dose (pMTD)
Phase II Treatment
Participants receive GOS or placebo (maltodextrin) at determined pMTD from about 30 days before transplant to about 4 weeks after transplant
Follow-up
Participants are monitored for safety and effectiveness after treatment, including overall survival and incidence of chronic GVHD
Treatment Details
Interventions
- Galacto-oligosaccharide
- Maltodextrin
Galacto-oligosaccharide is already approved in European Union, United States for the following indications:
- Infant nutrition
- Food additive
- Dietary supplement
- Food additive
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor